Qiming Venture Partners and Its Investors Named to 36Kr's 2025 China Industrial Investors Annual List
The list aims to identify investment firms and investors who embrace patience and foresight, and who are putting their convictions into practice to inject the strongest possible momentum into industries of the future.
Recently, 36Kr released its 2025 Annual Industrial Investor Rankings. The list includes China's Top 10 Future Industrial Investors and China's Top 10 Future Industrial Investors, aiming to identify investment firms and individuals who demonstrate patience and foresight, and who are actively powering the future of industry.
Qiming Venture Partners, along with Managing Partners William Hu and Alex Zhou, and Executive Director Chen Nan, were named to the 2025 Annual Industrial Investor Rankings.
Qiming Venture Partners
Selected for
Top 30 AI Industrial Investors in China
Top 30 Embodied Artificial Intelligence Industrial Investors in China
Top 30 Advanced Manufacturing Industrial Investors in China
Top 20 Life Sciences Industrial Investors in China
William Hu, Managing Partner of Qiming Venture Partners
Selected for
Top 20 Life Sciences Industrial Investors in China
Alex Zhou, Managing Partner of Qiming Venture Partners
Selected for
Top 30 AI Industrial Investors in China
Top 30 Embodied Artificial Intelligence Industrial Investors in China
Chen Nan, Executive Director of Qiming Venture Partners
Selected for
Top 30 Advanced Manufacturing Industrial Investors in China
2025 Annual Industrial Investor Rankings
36Kr's research institute relied on its proprietary system to collect and analyze multi-dimensional data on investment firms, including fund size, fundraising activity, deal volume and value within specific industries, industry concentration, portfolio company development and financing performance, and exit returns. Based on this analysis, the institute selected the ranked investment firms and individuals.
In 2025, China and the world stand at a critical inflection point of a new round of "technology and investment co-driving industrial revolution." Investment institutions have entered a new historical cycle of advancing "technological innovation and industrial deployment" — with future industries such as artificial intelligence, embodied artificial intelligence, advanced manufacturing, and life sciences attracting forward-looking capital allocations from market-driven investors and beyond.
Source | 36Kr
Past Highlights
Qiming Honors | Qiming Venture Partners and Its Investors Named to 36Kr 2025 Annual China Equity Investment Industry Rankings Qiming Honors | Qiming Venture Partners and Multiple Portfolio Companies Named to 2024-2025 China Technology Industry Investment Rankings Qiming Honors | Qiming Venture Partners and Four Portfolio Companies Win 2025 Sci-Tech Innovation Golden Bull Awards
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management of $9.5 billion. Since its inception, the firm has focused on investing in early and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies. More than 210 of these have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many of Qiming Venture Partners' portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), Insta360 (688775.SH), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinocellTech (688520.SH), Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, and others.